Eli Lilly Acquires Centessa Pharmaceuticals for Up to $7.8 Billion to Boost Sleep Medicine Pipeline

Eli Lilly moved to stake out a dominant position in the competitive race to treat sleep disorders, striking a deal to acquire Centessa Pharmaceuticals for up to $7.8 billion and securing what it described as one of the most compelling mechanistic opportunities in modern neuroscience.

The Indianapolis-based drugmaker offered $38 per share in cash plus a contingent value right potentially worth an additional $9 per share, totaling up to $47 per share. That upfront cash consideration represents an aggregate equity value of approximately $6.3 billion and carries a 40.5% premium to Centessa's 30-day volume-weighted average trading price through March 30. The acquisition is expected to close in the third quarter of 2026, pending approval from Centessa shareholders, a U.K. High Court sanction, and customary regulatory clearances.

At the center of the deal is cleminorexton, formerly known as ORX750, an oral selective orexin-2 receptor agonist that produced a potentially best-in-class profile in Phase 2a clinical studies across narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia. A second pipeline asset, ORX142, sits at an earlier development stage. The $9-per-share CVR is contingent on U.S. FDA approval of either cleminorexton or ORX142 before January 1, 2030, a structure that spreads late-stage regulatory risk between Lilly and Centessa shareholders while preserving meaningful upside if the science holds.

CEO David Ricks drew a pointed analogy to Lilly's GLP-1 franchise, the blockbuster metabolic drug class generating tens of billions in annual revenue from Zepbound and Mounjaro. "We see a broader potential for this pathway, maybe a little bit of analogy to GLP-1, in a way that, you know, sleep and wakefulness are like core to our functioning," Ricks said, adding that disruptions to either create cascading health problems. He described applications potentially extending into Alzheimer's disease, depression, and conditions involving impaired daytime executive function, a prospect that could push the commercial ceiling well beyond narcolepsy alone.

Carole Ho, Lilly's executive vice president and president of Lilly Neuroscience, framed the science as "a direct intervention on the master switch of the sleep-wake cycle," a characterization that reflects the company's confidence in the orexin pathway as a platform franchise rather than a single-indication drug.

The orexin space is competitive. Takeda Pharmaceutical's oveporexton, also an OX2R agonist, is currently under FDA review following back-to-back Phase 3 wins and could receive approval later this year, well ahead of cleminorexton, which analysts do not expect to reach the market before 2028. Lilly concluded that Centessa's Phase 2a data was sufficiently differentiated to justify the premium even without first-mover advantage.

The Centessa deal is Lilly's third major acquisition of 2026, following agreements to buy cell-therapy company Orna Therapeutics and inflammation-focused Ventyx Biosciences. The company has been explicit that it is deploying GLP-1 profits to diversify aggressively beyond metabolic drugs.

For the estimated 200,000 Americans living with narcolepsy, a condition frequently misdiagnosed for years before patients receive proper care, the scale Lilly brings carries real weight. Existing narcolepsy therapies have generated persistent disputes over insurance coverage and significant out-of-pocket exposure for patients on restricted formularies. Whether Lilly's commercial infrastructure accelerates access or replicates the high-price playbook that has characterized specialty sleep drugs will define the real-world impact of the deal as cleminorexton advances toward its Phase 3 program.